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ABSTRACT  
A simple ultra-high performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS) method was developed and 
fully validated to simultaneously determine levothyroxine (LT4) and liothyronine (LT3) in human serum. Sample preparation was  done 
through protein precipitation with acetonitrile. HyPURITY C18 column was selected to achieve rapid separation for LT4 and LT3  within 4 min. 
Electrospray ionization (ESI) under multiple reaction monitoring (MRM) was used to monitor the ion transitions for LT4 (m/z 777.54→731.52), 
LT3 (m/z 651.64→ 605.65) and internal standard LT4-D3 (m/z 780.53 →734.19), operating in the positive ion mode. The method was proved 
to be accurate (82.35% to 113.56%) and precise (0.73% to 8.28%) over concentration range of 50.37 ng/ml – 300.13 ng/ml for LT4 and 0.5 
ng/ml – 50.37 ng/ml for LT3. The validated method could be applied for pharmacokinetic study or bioequivalence testing of combination  
products of LT4 and LT3. 
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INTRODUCTION 
Hypothyroidism is a state of deficiency of endogenously 
produced thyroid hormone and affects nearly 5.0% of the 
world population 1. Hypothyroidism management is done 
with monotherapy of levothyroxine (LT4). Levothyroxine is a 
synthetic analogue of thyroxine hormone and is used in 
concentration equivalent to thyroid stimulating hormone 
(TSH) present in the body 2, 3. Although, treatment with 
LT4achieve normal TSH levels, but 5–10% of individuals 
with hypothyroidism are not satisfied with monotherapy, 
and do not consider their previous well-being to be restored 
4-6. The more potent thyroid hormone is triiodothyronine 
(T3), 20% of which is produced by the thyroid gland and rest 
80% is produced by conversion of thyroxine (T4) to T3 in the 
liver 7. So under physiological conditions, a treatment 
dependent singly on LT4 would not give optimum results as 
required level of T3 will not be met. Several studies in the 
past demonstrated that treatment with combination of LT4 
and liothyronine (LT3), the man made form of T3 is 
preferred compared to monotherapy by LT4 4-6. First, studies 
in thyroidectomized rats have demonstrated that normal 
tissue concentrations of T4 and T3 can be reached by 
continuous infusions of LT4 and LT3 simultaneously 7. In 
1970s, human studies on the treatment of hypothyroidism 
used pharmacological doses of thyroid hormone 
combinations. Several clinical trials demonstrated that 
combinations of LT4 and LT3 are beneficial and considered as 
answer to the relatively frequent complaint of the 
persistence of hypothyroid symptoms with LT4 alone, 
despite normal TSH levels 8. Combination therapy with LT4 
and LT3improved several indexes of quality of life, mood, 
and psychometric performance 4. Considering this, several 
combination products of LT4 and LT3are available in market 
and continuous monitoring of serum levels of LT4 and LT3 
are required for effective therapy. Most clinical laboratories 
uses automated radioimmunoassay kits9, HPLC 10 and HPLC-
MS/MS 11 for measurement of free or total T4 and T3, 
however most of the developed methods are focused on 
determination of thyroid hormones from diagnostic purpose. 
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Till date no analytic technique is available for determination 
of LT4 and LT3 in human serumfrom pharmacokinetic or 
bioequivalence purpose. In the present research, we have 
developed rapid and sensitive UPLC-MS/MS method for 
simultaneous determination of LT4 and LT3 in human serum 
using Levothyroxine D3 Hydrochloride (LT4-D3) as internal 
standard (Fig. 1). The method could be utilized for 
determination of bioequivalence and serum concentrations 
following administration of LT4 and LT3 combination 
therapy.
 
 
Figure 1: 
MATERIAL AND METHODS 
Materials  
LT4sodium (99.82%), LT3 (99.81%) and internal standard 
LT4-D3 hydrochloride (99.65%) were obtained from Vivan 
Life Sciences Pvt. Ltd. (Mumbai, India). Acetonitrile, 
methanol and ethyl acetate of HPLC Grade was obtained 
from Merck Ltd. (India). HPLC water was produced by Milli 
Q purification system in laboratory using Millipore, 
(Bellerica, MA, USA).Glacial acetic acid(SQ Grade), Liquor 
Ammonia(SQ Grade) was obtained from Thermo Fisher 
Scientific India Pvt. Ltd (India).All other reagents were of 
analytical grade. Human Serum containing odium heparin as 
anticoagulant was procured from Darpan Diagnostic 
Research Solution (Gujrat, India) and stored at -20 ± 5ºC and 
-70± 15ºC. 
Chromatographic and Mass Spectrometric Conditions 
The samples were chromatographed and analyzed on UPLC 
(Waters Corporation, MA, USA) with MS detector (Synapt; 
Waters, Manchester, UK) havingHypurityC18 (50 X 4.6mm, 
5micrometer) UPLC column. The column oven and auto-
sampler temperature were maintained at 40 ºC ± 5ºC and 
5ºC ± 0.5ºC, respectively. The sample injection volume was 
20 µL and elution was performed using 0.1% glacial acetic 
acid in water (mobile phase A):acetonitrile(mobile phase B) 
mixture (65:35, v/v) with isocratic flow rate of 0.8 mL/min 
and total run time of 4 min. Waters Q-TOF Premier 
(Micromass MS Technologies, Manchester, UK) mass 
spectrometer was used for m/z analysis. Different 
parameters are set as follow, desolvation gas at 950 l/h, the 
cone gas at 20 l/h, source temperature at 150°C, capillary 
voltage at 4.0 kV and sample cone voltage at 30 V.  LT4, LT3 
and LT4-D3were analyzed by mass spectrometer with 
electro spray ionization in positive polarity mode. 
Precursor→product ion transition was found out to be m/z 
777.54→731.52 for LT4, m/z 651.64→ 605.65 for LT3, and 
m/z 780.53 →734.19 for LT4-D3 at collision energy of 18 eV 
and dwell time of 0.1 s. Mass Lynx software version 4.1 was 
used for acquisition of The chromatographic data. The best–
fit lines using weighting factor (1/Concentration2) linear 
least square regression analysis were obtained by peak area 
ratio of LT4 and LT3 to IS (LT4- D3). In serum samples the 
concentration of Levothyroxine and Liothyronine was 
estimated using linear regression factors to corresponding 
calibration curve. 
Calibration and Quality Control Samples 
Stock solution of LT4 and LT3 was prepared by dissolving 
the known quantity of drugs in 1ml of aqueous ammonia 
solution (5%).Blank human serum was used to prepare 
calibration standards and QC samples by diluting 
corresponding stock solutions. Working dilutions for serum 
spiked calibration curve were prepared in the range of 50.37 
ng/ml – 300.13 ng/ml for LT4 and in concentration range of 
0.5 ng/ml – 50.37 ng/ml for LT3. Dilutions for LOQQC, LQC, 
MQC and HQC quality control samples were also prepared 
from respective stock solution by suitable dilution. LT4-D3 
(IS) dilution was prepared at concentrations of 250ng/ml.  
All stock solutions, calibration standards and QC samples 
were cryo-preserved under -80 °C 
Sample Preparation  
Hundred microliter of LT4-D3, 100µL 0.5N HCl and 800µL of 
acetonitrilewas added to 200µL of sample (calibration, QC or 
serum) and vortexed for 5.0 minutes. After adding 1.5mL of 
ethyl acetate, the mixture was centrifuged at 4000rpm at 4ºC 
for 5 minutes. The 2mL supernatant was collected and 
allowed to dry at 20psi pressure and 50°C in nitrogen 
evaporator. Finally, the dried sample was reconstituted with 
400 µL mixture of 0.1% glacial acetic acid in water and 
acetonitrile (65:35 v/v). The sample was then transferred 
into labelled auto sampler vials and inject into LCMS/MS 
system. 
Method Validation 
The method was validated in terms of selectivity, sensitivity, 
linearity, precision and accuracy. The precision of the 
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method was evaluated with repeatability and intermediate 
precision assays. Within a day three concentrations in linear 
range and in seven replicates were used to evaluate 
repeatability whereas 3 concentrations in three replicates 
for a time interval of seven days were used to estimate 
intermediate precision. Accuracy was determined through 
intra-assay and inter-assays based on the standard solutions 
of analytes in three concentration levels. ICH guidelines 
were followed for validation of all parameters like 
selectivity, linearity, precision, accuracy, recovery, stability, 
detection limit, quantitation limit and ruggedness 12. 
RESULTS AND DISCUSSION 
Sample Preparation and Method Development  
Sample preparation is a key procedure for the determination 
of analytes in biological samples. In the present work for 
MS/MS determination, we have used simple liquid 
extraction and sample preparation procedure, to eliminate 
the possible interfering substances. Protein precipitation via 
acetonitrile was found suitable for the estimation of LT4, 
LT3 and LT4-D3 in serum. As shown in Fig. 2, a clean 
chromatograms of LT4, LT3 and LT4-D3 in serum were 
obtained. HyPURITY C-18 column and high pressure applied 
in UPLC allowed rapid detection of LT4, LT3 and LT4-D3 
with excellent peak shape. The composition of mobile phase 
was optimized through several trials to obtain symmetric 
peaks with good response. Elution with 0.1% glacial acetic 
acid in water: acetonitrile mixture (65:35, v/v) with flow 
rate of 0.8 mL/min allowed separation of LT4, LT3 and LT4-
D3 at retention time of 2.65, 1.67 and 2.56, respectively. The 
total run time was 4 min. 
The analysis of all the analytes were done in positive ion 
mode. Protonated molecules [M+H]+ at m/z 651.64 for LT3, 
777.54 for LT4 and 780.53 for LT4-D3 were selected as the 
precursor ions for further fragmentation. ESI-MS/MS spectra 
in positive ion mode demonstrated that the dominant 
fragment of LT3 was m/z 605.65, for LT4 was m/z731.52 
and for LT4-D3 was 734.19. The most abundant ions, 
[M+H−HCOOH]+, represent the loss of HCOOH in thyroid 
hormones (Table 1). 
 
Table 1:  Precursor→ Product ion transition for LT4, LT3 and LT4-D3 using Mass spectrometry 
Mass (Da)  Levothyroxine  Liothyronine  Levothyroxine D3 
Parent Mass   777.54  651.64  780.53 
Product Mass   731.52  605.65  734.19 
 
 
Figure 2: 
Specificity and Selectivity 
Eight lots of serum including haemolyzed and lipemic serum 
anticoagulant were evaluated and none showed significant 
interfering peaks at the retention time of LT4, LT3 and LT4-
D3, demonstrating that the developed method is specific and 
selective.  
Linearity 
The linearity determination of the LT4 and LT3 was done 
using weighted least square regression analysis of standard 
plot associated with eight-point standard curve. The 
calibration was found to be linear from 5.01ng/mL 
to300.13ng/mL for LT4 and from 0.50ng/mL to 50.37ng/mL 
for LT3. Weighed least square regression analysis with 
weighting factor of 1/Concentration² was used to determine 
best–fit calibration lines of chromatographic response 
versus concentration. As shown in Table 2, during the course 
of validation the coefficient of correlation (r2) was found to 
be consistently greater than or equal to 0.98, which is within 
acceptable limits. 
 
Table 2:  Linearity and Ruggedness data of LT4 and LT3 in serum samples 
 
 
Analyte 
 Calibration 
range 
(ng/mL) 
 
Slope 
 
Intercept 
(ng/mL) 
 
R2 
 
LOQ 
(ng/mL) 
 
Standard 
Solution 
 
LT4 
 
4.90 - 300.69 
 
0.00989103 
 
0.00209728 
 
0.995917 
 
4.90 
 
Ruggedness  LT4  5.01 - 300.13  0.01048940  0.00293423  0.996859  4.91  
Standard 
Solution 
 
LT3 
 
0.48 - 53.39 
 
0.0104997 
 
0.00132268 
 
0.995998 
 
0.48 
 
Ruggedness  LT3  0.50 - 50.37  0.01140690  0.000737368  0.993674  0.47  
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Limit of Quantification (LOQ) 
LOQ is the lowest point of calibration curve representing 
lowest concentration that can be measured with precision 
and accuracy. The LOQ for LT4 and LT3, assessed by 3 
calibration curve standards, was found out to be 4.9 ng/mL 
and 0.48ng/mL, respectively. The LLOQ precision forLT4 and 
LT3 was0.66 % and 2.42 %, respectively whereas the ULOQ 
precision for LT4 and LT3 was 1.40 % and 0.35 %, 
respectively which are within acceptance limits. 
Accuracy and Precision 
The results of within batch and between batch accuracy and 
precision of the assay over the concentration range of 
LOQQC, LQC, MQC and HQC samples of LT4 and LT3 are 
shown in Table 3. Accuracy of the assay was measured as the 
absolute value of the calculated mean values of the QC 
samples to their respective nominal values, expressed as 
percentage using internal standard area ratio method and 
the precision was measured as the percent coefficient of 
variation. The within batch accuracy ranged from 88.77% to 
109.58% and 82.35% to 112.78% for LT4 and LT3, 
respectively, whereas the between batch accuracy ranged 
from 86.69% to 109.58% and 82.35% to 113.56% for LT4 
and LT3, respectively. The within and between batch 
precision was found to be 0.86% to 2.13% range and 0.73% 
to 8.28% range for LT4 and LT3, respectively. Thus data 
obtained indicate that the developed method is accurate and 
precise. 
 
Table 3: Precision and Accuracy Assay data for LT4 and LT3 (n= 6) 
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 15.37  13.69  0.18  1.30 89.07  1.50 1.68  0.12 7.07  111.67 
 122.93  119.44  1.04  0.87 97.16  22.75 23.93  0..48 1.99  105.19 
 
245.85  269.41  3.50  1.30 
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8 
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0.51 0.49  0.04 8.28  96.73 
 15.37  13.64  0.15  1.08 88.77  1.50 1.69  0.05 3.16  112.78 
 122.93  118.95  1.05  0.88 96.77  22.75 23.93  0.46 1.93  05.16 
 
245.85  266.34  2.30  0.86 
108.3
3 
 45.50 46.80  0.34 0.73  102.86 
aPrecision as RSD % (or CV%) = (standard deviation divided / mean amount found) * 100 
b Accuracy=  (Amount found/ nominal amount)* 100 
Recovery 
The percentage recovery of LT4 and LT3 was calculated by 
determining the peak area response of spiked (extracted) 
quality control samples (LQC, MQC and HQC) against the 
peak area response of sample prepared by adding suitable 
amount of  (extracted reconstituted) quality control samples 
(LQC, MQC and HQC) of equivalent concentrations (Table 4). 
The percent recovery of LT4 and LT3 at LQC, MQC and HQC 
quality control samples were 49.69%, 50.20%, 55.51% and 
56.37%, 56.36%, 56.64%, respectively. For inter quality 
control sample of LT4 and LT3, the % CV for recovery was 
6.22% and 0.27% respectively, and is within limits. The 
Percent Mean of recovery were 51.80% and 56.46% which 
are within limits. The percentage recovery of LT4-D3 
estimated by same procedure was found to be 50.45 %.  
 
Table 4: Percentage Recovery for LT4 and LT3 
QC  ID  Analyte  A  (% CV)  B  (% CV)  
Extraction Recovery 
(%RE)[A/B×100] 
LQC 
 Levothyroxine  22177.50 (3.31)  46158.33, (0.53)  48.05 
 Liothyronine  3124.17 (1.99)  5572.33 (2.03)  56.07 
MQC 
 Levothyroxine  197159.50 (1.14)  404294.17 (1.57)  48.77 
 Liothyronine  43036.00 (1.31)  77025.00 (0.67)  55.87 
HQC 
 Levothyroxine  454419.17 (0.82)  837801.17 (0.80)  54.24 
 Liothyronine  88219.17 (1.63)  152761.50 (5.72)  57.75 
A: Mean Area response of six replicate samples prepared by spiking before extraction. 
B: Mean Area response of six replicate samples prepared by spiking in extracted blank plasma.    CV: Coefficient of variation.  
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Ruggedness 
The ruggedness of the extraction procedure and 
chromatographic method was evaluated by analysis of a 
batch of six sets of quality control samples and a set of 
calibration standard using a different column (same type) by 
another analyst. The intra batch accuracy ranged from 
86.69% to 106.80% for LT4 and from 99.67% to 113.56% 
for LT3. The intra batch precision ranged from 0.47% to 
2.21% for LT4 and from 1.27% to 7.40% for LT3. The results 
(Table 2) clearly depicted that the batch was in the 
acceptance criteria for linearity, accuracy and precision data 
of the quality control samples. So the method met the 
criteria for ruggedness.  
Stability 
Freeze thaw stability 
Three freeze-thaw cycles were performed to determine the 
stability of the spiked serum samples. LQC and HQC stability 
samples were taken in four replicates, kept at -80°C ± 10°C 
and then analyzed after three freeze thaw cycle against QC 
samples and freshly spiked calibration curve standards. The 
range of comparative stability was from 91.72% to 109.05% 
for LT4 and 103.24% to 113.33% for LT3, (Table 5). 
Bench top stability 
The bench-top stability was determined by analyzing four 
replicates of LQC and HQC stability sampleskept at room 
temperature for 4 hours against the freshly spiked 
calibration curve standards and QC samples (Table 5).The 
comparative stability ranged from 91.72% to109.77% and 
103.36% to 111.33% forLT4 and LT3, respectively. 
In-Injector stability 
Auto sampler stability was evaluated by analysis of LQC and 
HQC stability samples (four replicates), after processing and 
keeping them in Auto sampler for 2 Days 1 Hours & 
11minutes, and then analysis was done against freshly 
spiked calibration curve standards and QC samples (Table 
5). Comparative stability was found to be ranged from 88.79 
% to 109.05% and 103.24% to 113.33% for LT4 and LT3, 
respectively.
 
Table 5: Stability data for Levothyroxine and Liothyronine under different conditions, (n=6) 
S
ta
b
il
it
y
 
S
to
ra
g
e
 C
o
n
d
it
io
n
s 
LT4 LT3 
M
e
a
n
 S
ta
b
il
it
y
 
S
a
m
p
le
  c
o
n
c.
 
(n
g
/m
L
) 
%
 N
o
m
in
a
l 
M
e
a
n
 C
o
m
p
a
ri
so
n
 
sa
m
p
le
  c
o
n
c.
  ±
 S
D
 
%
 N
o
m
in
a
l 
%
 m
e
a
n
 c
h
a
n
g
e
 
%
  s
ta
b
il
it
y
 
M
e
a
n
 S
ta
b
il
it
y
 
S
a
m
p
le
  c
o
n
c.
 
(n
g
/m
L
) 
%
 N
o
m
in
a
l 
M
e
a
n
 C
o
m
p
a
ri
so
n
 
sa
m
p
le
  c
o
n
c.
  ±
 S
D
 
%
 N
o
m
in
a
l 
%
 m
e
a
n
 c
h
a
n
g
e
 
%
  s
ta
b
il
it
y
 
Freeze 
and thaw 
After 3 
cycles 80°C 
± 10°C 
13.69 89.09 
14.06± 
0.17 
91.72 -2.63 97.13 1.62 107.83 
1.70 ±  
0.08 
113.33 
-
4.70 
95.15 
266.10 108.24 
269.66 
± 2.52 
109.05 -3.56 99.26 47.45 104.28 
46.18  ±  
0.28 
103.24 2.75 101.01 
Bench 
Top 
4 hr at 25 ± 
5°C (Room 
temp) 
14.05 91.40 
14.06 
±  0.17 
91.72 -0.07 99.65 1.73 115.50 
1.70± 
0.08 
113.33 1.76 101.91 
267.22 108.69 
269.66 
±2.52 
109.05 -0.91 99.67 45.11 99.14 
46.18 ± 
0.28 
103.24 
-
2.31 
96.02 
Extracted 
Sample  
stability 
Autosampler 
(6°C, 49 hrs 
11min) 
13.65 88.79 
14.06 
± 0.17 
91.72 -2.91 96.81 1.62 108.00 
1.70± 
0.08 
113.33 
-
4.70 
95.29 
264.57 107.62 
269.66 
±2.52 
109.05 
-
2.077 
98.69 46.94 103.15 
46.18± 
0.28 
103.24 1.64 99.91 
% Mean change = Mean stability samples - Mean comparison samples/mean comparison samples) ×100. 
 
 
CONCLUSION 
We have successfully developed a specific, sensitive and 
rapid UPLC/ESI/MS/MS method for quantification of LT4 
and LT3 in human serum and have validated the same. This 
assay method allowed real time analysis with simple liquid 
extraction procedure, isocratic chromatography condition 
using a reversed-phase column. An excellent performance 
was noted in terms of selectivity, linearity, precision, 
accuracy, recovery, quantitation limit and stability. Most 
importantly, short analysis run time of this particular 
method gives it an edge over all previously reported 
methods. Thus, this method is most appropriate for 
pharmacokinetic study, bioequivalence study and 
therapeutic monitoring of thyroid hormones.  
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